$990.2 M

DVAX Mkt cap, 14-Jun-2018

$165 K

Dynavax Technologies Corporation Revenue Q1, 2018
Dynavax Technologies Corporation Net income (Q1, 2018)-39 M
Dynavax Technologies Corporation EBIT (Q1, 2018)-38.3 M
Dynavax Technologies Corporation Cash, 31-Mar-201836.1 M
Dynavax Technologies Corporation EV1.1 B

Dynavax Technologies Corporation Revenue Breakdown

Embed Graph

Dynavax Technologies Corporation revenue breakdown by business segment: 8.0% from Service and license revenue, 88.5% from Collaboration revenue and 3.5% from Other

Dynavax Technologies Corporation Financials

Dynavax Technologies Corporation Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

11.3 m11 m4.1 m11 m327 k

Revenue growth, %

(2%)(63%)173%

R&D expense

50.9 m84.6 m86.9 m84.5 m65 m

General and administrative expense

25.9 m17.4 m22.2 m37.3 m27.4 m

Operating expense total

76.8 m102 m109.1 m121.8 m96.3 m

Depreciation and amortization

1.2 m

EBIT

(66.5 m)(91.3 m)(105.1 m)(110.7 m)(96 m)

EBIT margin, %

(591%)(828%)(2594%)(1003%)(29359%)

Interest expense

35 k572 k572 k

Interest income

116 k191 k205 k755 k1.3 m

Net Income

(66.7 m)(90.7 m)(106.8 m)(112.4 m)(95.2 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

3.5 m3 m2.2 m627 k1.6 m1.2 m942 k2.6 m162 k148 k105 k165 k

R&D expense

11.8 m13.2 m23.6 m28.1 m22.2 m19.7 m24.1 m20.1 m22.8 m23.2 m16.3 m14.8 m19 m

General and administrative expense

5.8 m4.2 m4.1 m4.1 m4.9 m5.1 m5.5 m8.2 m9.2 m11.8 m6.5 m5.6 m16.9 m

Operating expense total

18.5 m17.5 m27.9 m32.3 m27.1 m24.8 m29.6 m28.2 m31.9 m35 m25.6 m20.4 m38.5 m

EBIT

(15.6 m)(14 m)(24.9 m)(30.1 m)(26.5 m)(23.2 m)(28.4 m)(27.3 m)(29.3 m)(34.8 m)(25.5 m)(20.3 m)(38.3 m)

EBIT margin, %

(399%)(815%)(1362%)(4219%)(1499%)(2394%)(2897%)(1105%)(21505%)(17197%)(19353%)(23221%)

Interest expense

24 k247 k263 k62 k247 k263 k62 k1.2 m

Interest income

37 k65 k55 k42 k27 k18 k33 k225 k220 k170 k145 k235 k740 k

Net Income

(15.7 m)(13.8 m)(24.8 m)(29.8 m)(26.2 m)(23.6 m)(30.1 m)(27 m)(29 m)(34.7 m)(25.3 m)(20.3 m)(39 m)

Dynavax Technologies Corporation Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

23.1 m49.5 m44.8 m24.3 m26.6 m

Accounts Receivable

1.6 m727 k1.4 m

Inventories

1.4 m4.1 m2.4 m6.8 m312 k

Current Assets

192.4 m127.4 m199.9 m89.6 m198 m

PP&E

8.7 m7.9 m13.8 m17.2 m16.6 m

Goodwill

2.6 m2.3 m2 m2 m2.2 m

Total Assets

204.6 m138.3 m216.6 m109.7 m218.8 m

Accounts Payable

1.9 m1.2 m3.4 m3.8 m4.5 m

Short-term debt

Current Liabilities

16.2 m20.3 m28.8 m20 m18.6 m

Long-term debt

9.6 m

Non-Current Liabilities

2.1 m17.5 m769 k443 k

Total Debt

9.6 m

Total Liabilities

18.3 m37.8 m29.6 m20.5 m19.2 m

Additional Paid-in Capital

688.4 m695.1 m889.7 m905 m1.1 b

Retained Earnings

(502.2 m)(592.9 m)(699.7 m)(812.2 m)(907.3 m)

Total Equity

186.3 m100.5 m187.1 m89.2 m199.5 m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.1 x1.4 x1.2 x1.2 x1.1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

12.2 m26.8 m17 m19.7 m14.7 m36.5 m103 m38.9 m24.8 m23 m21.5 m37.7 m36.1 m

Accounts Receivable

2.2 m1.7 m1.3 m727 k909 k657 k1.2 m1.2 m

Inventories

550 k

Current Assets

79.8 m181.7 m160.6 m134.9 m102 m97.9 m224.3 m170.7 m147.1 m117.5 m89.7 m132.2 m255.4 m

PP&E

8.5 m8.6 m8.8 m8.1 m7.5 m8.9 m11.6 m15.9 m17.4 m18.7 m16.6 m16.8 m17.1 m

Goodwill

2.5 m2.6 m2.6 m2.4 m2 m2.1 m2.1 m2.1 m2.1 m2.1 m2 m2.1 m2.3 m

Total Assets

91.7 m193.6 m173.5 m146.9 m112.2 m109.5 m238.9 m189.6 m167.6 m139.3 m110.1 m152 m295.3 m

Accounts Payable

1.3 m1.9 m1.9 m5 m3.3 m2.3 m2.4 m3.5 m4.5 m3.8 m1.5 m681 k2.3 m

Current Liabilities

15.6 m16 m20.2 m22.8 m20.5 m22 m19.7 m24.5 m28.2 m30.5 m12.4 m11.1 m23.5 m

Long-term debt

8.9 m8 m9.6 m99.2 m

Total Debt

8.9 m8 m9.6 m99.2 m

Total Liabilities

19.3 m19.7 m22.8 m25.3 m37.1 m35 m27.7 m25.2 m28.8 m31 m12.7 m11.4 m129.4 m

Additional Paid-in Capital

561.7 m689.7 m691.4 m693.1 m697.1 m720 m886.6 m893.3 m897 m901.1 m938.2 m1 b1.1 b

Retained Earnings

(489.2 m)(516.1 m)(540.8 m)(570.6 m)(619.2 m)(642.7 m)(672.9 m)(726.8 m)(755.7 m)(790.4 m)(837.5 m)(857.8 m)(946.3 m)

Total Equity

74.5 m211.2 m164.4 m138.8 m108.3 m97.4 m140.5 m165.9 m

Financial Leverage

1.5 x1.1 x1.2 x1.2 x1.3 x1.1 x1.1 x1.8 x

Dynavax Technologies Corporation Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(66.7 m)(90.7 m)(106.8 m)(112.4 m)(95.2 m)

Depreciation and Amortization

1.3 m1.4 m1.4 m2.3 m3.2 m

Accounts Receivable

(622 k)900 k(667 k)52 k

Inventories

677 k(2.7 m)1.6 m560 k(312 k)

Accounts Payable

(657 k)(523 k)1.2 m1.2 m(1.9 m)

Cash From Operating Activities

(58.7 m)(73.7 m)(92.6 m)(107.1 m)(77.5 m)

Purchases of PP&E

(669 k)

Cash From Investing Activities

(51.4 m)90.6 m(85.8 m)86.2 m(108.7 m)

Cash From Financing Activities

125.4 m9.9 m174 m531 k187.8 m

Interest Paid

720 k720 k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(15.7 m)(13.8 m)(24.8 m)(29.8 m)(26.2 m)(23.6 m)(30.1 m)(27 m)(29 m)(34.7 m)(25.3 m)(39 m)

Depreciation and Amortization

823 k

Accounts Receivable

1.3 m727 k909 k657 k1.2 m1.2 m

Inventories

(238 k)

Accounts Payable

1.9 m5 m3.3 m2.3 m2.4 m3.5 m4.5 m3.8 m1.5 m349 k

Cash From Operating Activities

(29.9 m)

Purchases of PP&E

(897 k)

Cash From Investing Activities

(59.7 m)

Cash From Financing Activities

98.8 m

Interest Paid

813 k

Dynavax Technologies Corporation Ratios

USDY, 2018

EV/EBIT

-27.5 x

EV/CFO

-35.3 x

Financial Leverage

1.8 x
Report incorrect company information

Dynavax Technologies Corporation Operating Metrics

FY, 2016

Patents (US)

30

Patents (foreign)

260

Patents Pending

40

Phase I Trials Products

2

Phase II Trials Products

3

Phase III Trials Products

1

Preclinical Phase Products

2
Report incorrect company information